Cycle on Jul 1, 2026

I will start by listing the threads for this topic to see if there are active threads or watches that we need to address in this cycle.

I will read the existing notes in the topic to see what prior findings are documented and what exact slugs we have.

I see we have several active threads/watches and a number of existing findings. Let's check the watches that might have fired or are close to firing: 1. `Amgen Tavneos FDA hearing submission and public docket close`: Fire date: June 29, 2026. The watch title is `Amgen Tavneos FDA hearing submission and public docket close`, trigger: "Fires when Amgen submits its evidence and the public docket closes on June 29, 2026." Let's search to see what happened with Tavneos and Amgen. 2. `Sobi BLA resubmission for NASP in uncontrolled gout` 3. `Achieve Life Sciences NDA resubmission for cytisinicline in smoking cessation` 4. Let's do some searches for new clinical, regulatory, or public health updates over the last few days (since June 29/30, today is July 1, 2026). Let's search for "Amgen Tavneos", "Tavneos FDA", "Tavneos CHMP", "Replimune RP1", "Capricor deramiocel", "MoonLake sonelokimab", "Zepzelca", "Operation Trailblazer", and other general FDA, clinical trial, and public health updates. Let's run a web search using `sort="recent"` and `freshness="week"`.I will perform a web search to track recent updates on Amgen's Tavneos, specifically regarding the FDA hearing submission and public docket close that was scheduled for June 29, 2026, as well as any other recent developments in late June or early July 2026.

The search results show that: 1. The deadline for Amgen's hearing submission has been extended to **July 29, 2026** (it was previously June 29, 2026). 2. "Those results will be shared with the FDA as part of our hearing submission due by July 29 and submitted for publication," a spokesperson said. 3. The *New England Journal of Medicine* (NEJM) on Monday (June 29, 2026) retracted the pivotal trial paper ("ADVOCATE") for Tavneos after the FDA's investigation found patient outcome data was altered and trial irregularities/GCP breaches occurred. 4. Let's fetch some of these articles to get precise quotes and details. Let's fetch `https://www.medpagetoday.com/rheumatology/generalrheumatology/121980` or `https://www.bioworld.com/articles/732242-nejm-paper-on-tavneos-pivotal-trial-retracted-by-academic-authors` or another. Let's search for "NEJM Retracts Tavneos Trial Paper as FDA, EMA Both Move to Pull Amgen Drug From Market" or use `web_fetch`. Let's fetch `https://www.bioworld.com/articles/732242-nejm-paper-on-tavneos-pivotal-trial-retracted-by-academic-authors` or another available URL. Let's do a search for the exact retraction details and the July 29 extension. I'll search for the BioWorld article and Applied Clinical Trials article. I can fetch them or search for more details. Let's search for: `"NEJM Retracts Tavneos Trial Paper as FDA, EMA Both"` to see if we can read the content or fetch a similar URL. I will fetch `https://www.reuters.com/legal/litigation/medical-journal-retracts-paper-amgens-tavneos-drug-trial-after-fda-findings-2026-06-29/` if it's in the results or fetch one of the provided URLs. Let's do a search first to get some more precise URLs or fetch one of the ones in the search results. Wait, the URL `https://www.reuters.com/legal/litigation/medical-journal-retracts-paper-amgens-tavneos-drug-trial-after-fda-findings-2026-06-29/` is a good candidate. Let's check the other URLs. Let's fetch `https://www.fiercepharma.com/pharma/chmp-reverses-marketing-recommendation-amgens-tavneos-fda-hearing-looms` or `https://www.medpagetoday.com/rheumatology/generalrheumatology/121980`. Let's search for the exact text of these articles to see if we can find them. No, I should use `web_fetch` on one of the URLs. Let's try fetching the Reuters article or the FiercePharma article. Let's fetch the Reuters one. Wait, let's fetch the BioWorld one or FiercePharma. Let's try fetching the FiercePharma article: `https://www.fiercepharma.com/pharma/chmp-reverses-marketing-recommendation-amgens-tavneos-fda-hearing-looms` (Wait, let's look at the actual URL from the search result. The search result says: "Europe's CHMP reverses endorsement of Amgen's Tavneos" -> `https://www.fiercepharma.com/pharma/chmp-reverses-marketing-recommendation-amgens-tavneos-fda-hearing-looms` or similar. Let's search specifically for the URL or use search to find the exact URL. Let's do a search for the exact URL or fetch the one from the search results). Ah, let's do a search for: `site:fiercepharma.com Tavneos hearing July 29` to get the exact URL.I will search for the FiercePharma article on Tavneos to get its exact URL and then fetch it to gather precise details.

Excellent. I have the exact URLs: 1. `https://www.fiercepharma.com/pharma/medical-journal-retracts-tavneos-pivotal-study-article-complicating-amgens-defense-effort` 2. `https://www.fiercepharma.com/pharma/chmp-reverses-marketing-recommendation-amgens-tavneos-fda-hearing-looms` Let's fetch both of them to get the exact details. I will fetch the first one.

Let's fetch the other FiercePharma article to see the exact details of the CHMP recommendation to revoke Tavneos's marketing authorization. The title is `Europe's CHMP reverses endorsement of Tavneos as Amgen FDA hearing looms`. Let's fetch it.

Very interesting. We have several important pieces of information here: 1. **Amgen Tavneos update**: - The FDA hearing submission deadline has been extended to **July 29, 2026** (originally June 29, 2026). - On June 29, 2026, the *New England Journal of Medicine* (NEJM) formally retracted the pivotal ADVOCATE trial paper (Jayne et al., 2021) after an FDA investigation found database-lock and trial-unblinding violations (specifically, primary endpoint assessments in 9 patients were readjudicated after database lock and trial unblinding). - This fires our watch `Amgen Tavneos FDA hearing submission and public docket close` (thread ID `019ec855-5381-7936-a3b6-a40d207e679d`), which was set for June 29, 2026. Wait! The watch trigger was "Fires when Amgen submits its evidence and the public docket closes on June 29, 2026." But the deadline has been extended to July 29, 2026. I should record an event on it showing it's been extended to July 29, 2026. Or is it resolved? No, the submission didn't happen on June 29, it got extended to July 29, 2026. Wait, let's see if we should call `record_event` with `resolves: false` or `resolves: true` or update/register a new watch. Since the deadline got extended, we should keep it open or register a new one. Wait, the watch itself says "one_shot" and the fire date is June 29, 2026. Let's record an event on it explaining that the deadline was extended to July 29, 2026, and the NEJM retracted the pivotal paper on June 29, 2026. Let's set `resolves: false` (since the submission is now extended to July 29, 2026) or `resolves: true` and open a new watch for July 29, 2026. Let's set `resolves: true` to close the old one (as the June 29 date passed and the extension happened) and register a new watch for July 29, 2026. Actually, let's look at the parameters of `record_event`: `thread_id`, `cycle_id`, `summary`, `resolves`, `outcome`, `salience`. Wait, let's look at other updates from the CHMP meeting: - CHMP negative opinions on June 26, 2026: - **MaaT Pharma's MaaT013 (Xervyteg)** in acute Graft-versus-Host disease (aGvHD). MaaT plans to request a re-examination. - **Omeros's Yartemlea** (narsoplimab) in HSCT-TA-TMA. This matches our watch `EMA re-examination outcome on Omeros's narsoplimab in TA-TMA` (thread ID `019f0620-add-7ac7-9db1-1ce428418522`) and prior note `omeros-narsoplimab-chmp-negative-opinion-ta-tma`. Wait, the note says "On June 26, 2026, Omeros Corporation announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion...". So that was already recorded. - **Acadia Pharmaceuticals' Daybu (trofinetide)** in Rett syndrome: CHMP reversed its previous negative opinion and recommended approval following a re-examination. - CHMP positive opinions on June 26, 2026: - **Eli Lilly's Jaypirca (pirtobrutinib)** for chronic lymphocytic leukemia (CLL) across all lines of therapy. - **Incyte's Opzelura (ruxolitinib) cream** for moderate atopic dermatitis in adults. - **Aujemflu** (flu vaccine) - **Hopledo** (Parkinson's disease with motor fluctuations) - **Onswik** (type 2 diabetes) Let's search for other news from the last few days in health and science. Let's search for: - "Replimune RP1" (Advisory committee meeting scheduled for late July, PDUFA August 2, 2026) - "Capricor deramiocel" (Advisory committee meeting scheduled for July 29, 2026) - "Belite Bio tinlarebant" - "Definium DT120" - "Sobi NASP" - "Achieve Life Sciences cytisinicline" - "MoonLake sonelokimab" or "IZAR-1" - "GondolaBio PORT-77" - "USDA sterile fly production" or "New World screwworm" - "Ebola Bundibugyo" or "Ebola outbreak DRC" Let's perform a web search on some of these. I will search for "Replimune RP1 FDA", "Capricor deramiocel FDA", "Sobi NASP", "Achieve cytisinicline", and "Ebola Bundibugyo" to see if there are any recent updates. I will use `sort="recent"` and `freshness="week"`.

Ah! The search result is quite sparse. Let's do more targeted searches. Let's search for: - `"Replimune" OR "Capricor" OR "deramiocel" OR "RP1"` with `freshness="week"` - `"Ebola" "Bundibugyo"` with `freshness="week"` - `"screwworm"` with `freshness="week"` - `"Listeria" "cheese"` with `freshness="week"` Let's search for "Replimune" OR "Capricor" OR "deramiocel" OR "RP1" first. I will use `sort="recent"` and `freshness="week"`.

Let's fetch `https://musculardystrophynews.com/news/july-meeting-set-fda-advisory-committee-developer-discuss-deramiocel-dmd/` or look at the search results. Wait, let's look at `CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval`. Let's search for this to find the exact text or fetch it. Let's see if we can find the URL for that. The URL is: `https://stocktwits.com/news-articles/markets/equity/capr-stock-best-week-month-ceo-rules-out-conditional-deramiocel-approval/cZdDdk4RIa1` or similar. Let's do a search for: `"deramiocel" "conditional"` or `"Capricor" "conditional approval"` to see what Capricor's CEO said about the BLA and conditional approval. Let's do a web search.I will search for the recent statements from Capricor's CEO regarding the upcoming FDA Advisory Committee meeting on July 29, 2026, and the regulatory path for deramiocel, particularly the comment "no way" it gets only conditional approval.

Let's fetch `https://www.biospace.com/fda/capricor-thrown-for-another-loop-as-fda-sets-adcomm-for-dmd-cardiomyopathy-therapy` to see what's happening with Capricor. This relates to our prior note `fda-regulatory-pivot-advisory-committees-capricor-replimune` and the watch `FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy`. Let's fetch it.

Excellent. This is a very clear and detailed update on Capricor. Let's see what else: - The acting FDA Commissioner is Kyle Diamantas. He has said he wants more adcomms. - Capricor's adcomm is scheduled for **July 29, 2026** (which is also the target of our watch `FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy`). - Replimune's adcomm is for its twice-rejected advanced melanoma therapy RP1 prior to its **August 2, 2026** decision date (PDUFA). This corresponds to our watch `FDA advisory committee meeting and PDUFA date for Replimune's RP1 in advanced melanoma`. - Let's check the date of the Replimune adcomm. The article says "Replimune revealed that the FDA plans to schedule an adcomm for its twice-rejected advanced melanoma therapy RP1 prior to an Aug. 2 decision date." Let's search for the exact date of Replimune's adcomm. Let's do a search for: `"Replimune" "advisory committee"` to see if the exact date has been announced. I will do a web search.

This is very exciting. Let's see: 1. The FDA accepted the BLA resubmission for **Replimune's RP1** (plus nivolumab) in advanced melanoma, classifying it as a complete, Class 1 response. 2. The PDUFA target action date is **August 2, 2026**. 3. The FDA notified Replimune to expect an advisory committee meeting in **late July 2026**. 4. The FDA accepted the BLA resubmission for **Capricor's deramiocel** in Duchenne muscular dystrophy (DMD) cardiomyopathy, setting a PDUFA target action date of **August 22, 2026** (wait, let's verify if it's August 22, 2026, yes: "setting an Aug. 22 PDUFA decision date for Deramiocel in DMD"). 5. The FDA scheduled an advisory committee meeting for deramiocel on **July 29, 2026**. 6. This represents a significant shift under acting FDA Commissioner Kyle Diamantas, who has placed a renewed emphasis on advisory committee meetings for contested product applications ("FDA advisory panels are back, with new meetings for Replimune, Capricor"). Let's fetch `https://endpoints.news/fda-advisory-panels-are-back-with-new-meetings-for-replimune-capricor/` to read about this broader policy shift and get exact quotes. If Endpoints is behind a paywall, we can try to find another source or check what we can extract. Let's do a search for: `"Kyle Diamantas" "advisory panels" OR "advisory committee"` or similar to see if we can get more details about this shift. Or let's search: `"advisory panels are back" "Replimune"` or `"Kyle Diamantas" "adcomms"`. Let's run a web search.I will search for the Endpoints News article or other articles detailing the FDA's renewed emphasis on advisory committee meetings under acting Commissioner Kyle Diamantas.

Ah! Look at this: `FDA’s acting director of cell and gene therapies to leave position` (Endpoints News, 1 day ago): "Vijay Kumar, FDA's acting OTP director, says he's stepping down for reasons unrelated to agency turmoil, as the White House also weighs finalists for FDA commissioner. Acting FDA Commissioner Kyle Diamantas isn't interested in the permanent role. ... advisory committee meetings in the cases of Capricor and Replimune." Let's search for this article to read it and gather details about Vijay Kumar leaving, the OTP (Office of Therapeutic Products) director, and the White House weighing finalists for FDA commissioner. Let's search: `"Vijay Kumar" FDA OTP` or `"Vijay Kumar" "OTP"` or `"Vijay Kumar" "stepping down"`. I will do a web search.

Wow, this is huge news: 1. **Vijay Kumar**, the acting director of CBER's Office of Therapeutic Products (OTP), is stepping down after about a year in the job. 2. Underneath him, acting CBER Director **Karim Mikhail** will temporarily oversee OTP. 3. This is happening at a tumultuous time for the FDA, with the White House weighing finalists for the permanent FDA commissioner role, and acting FDA Commissioner **Kyle Diamantas** not interested in the permanent role. 4. Let's fetch `https://www.statnews.com/2026/06/29/vijay-kumar-exits-fda-office-of-therapeutic-products/` or `https://www.biospace.com/fda/fdas-cell-and-gene-therapy-head-steps-down-after-1-year` to get all the details and quotes. Let's fetch the BioSpace one first.

This is incredibly rich context. Let's see what else we can find. We have: - `fda-regulatory-pivot-advisory-committees-capricor-replimune` is our existing note slug. - Let's read the prior note body or write a fresh update for it. Wait, the prior note title was "The Post-Makary FDA Pivot: Reversals, Resubmissions, and a Return to Advisory Committees". We can reuse this slug `fda-regulatory-pivot-advisory-committees-capricor-replimune` to update it with: 1. The acceptance of Capricor's BLA resubmission for deramiocel, setting a PDUFA date of August 22, 2026, and scheduling the AdComm for July 29, 2026. 2. The acceptance of Replimune's third BLA resubmission for RP1, setting a PDUFA date of August 2, 2026, and notifying the company to expect an AdComm in late July. 3. The departure of Vijay Kumar, the acting director of CBER's Office of Therapeutic Products (OTP), who is stepping down after exactly one year (mutual decision with CBER and FDA leadership). 4. The broader trend: acting FDA Commissioner Kyle Diamantas is overseeing a pivot back to advisory committees for contested products, while the White House is weighing finalists for the permanent FDA commissioner position. Let's double-check if there are other updates on: - Sobi's NASP in uncontrolled gout. Sobi received a CRL on June 26, 2026. Is there any new update in the last few days? Let's check. - Achieve Life Sciences' cytisinicline. It received a CRL on June 22, 2026. Is there any new update? - MoonLake's sonelokimab. The Phase 3 IZAR-1 trial readout is expected in mid-2026. Let's do a search for MoonLake sonelokimab or "IZAR-1". - GondolaBio's PORT-77 PATHWAY trial. Let's do a search for GondolaBio or PORT-77. - USDA sterile fly production facility in Texas. Let's do a search for "screwworm". - Ebola outbreak in DRC (Bundibugyo strain). The search result from MedPage Today says: "A total of 1,274 cases and 360 deaths have been confirmed in Congo's Ebola outbreak...". Let's search for "Ebola Bundibugyo" or "Ebola Congo 2026" to see what is new. Let's do a web search for MoonLake sonelokimab and IZAR-1. I will use `sort="recent"` and `freshness="week"`.

Let's fetch `https://seekingalpha.com/article/4918139-moonlake-buy-sonelokimab-bla-submission-hs-september-and-label-expansion` to see if there is any update on the IZAR-1 psoriatic arthritis readout timing or details. It is a very recent article (5 days ago). Let's fetch it.

Ah, the summary was retrieved, but the full body of the article was not. No matter, the summary highlights: - BLA for sonelokimab in HS is expected by the end of September 2026. - The company has $357.9M in cash plus a recent $200M raise (completed in late June 2026). - Late-stage pipeline continues in PsA (Psoriatic Arthritis) and axSpA. - Let's check when the IZAR studies are expected to read out. The previous search results noted: "The company has additional data catalysts ahead, including topline Phase 3 IZAR program readouts in psoriatic arthritis in the third and fourth quarters of 2026..." This means the Phase 3 IZAR-1 trial readout of sonelokimab in psoriatic arthritis is expected in Q3/Q4 2026. Let's keep our watch `MoonLake Phase 3 IZAR-1 trial readout of sonelokimab in psoriatic arthritis` active (it has a fire date of August 31, 2026, which is in Q3 2026). Let's search for "Ebola Congo 2026" or "Ebola Bundibugyo" to see the latest case counts and clinical trial updates. This is related to the watch `Clinical trial initiation/readout for fast-tracked Bundibugyo Ebola vaccines` and prior note `bundibugyo-ebola-outbreak-drc-uganda`. I will do a web search.

This is a critical update on the Ebola outbreak: - The outbreak (declared on May 15, 2026) is caused by the **Bundibugyo virus strain**. - As of July 1, 2026 (today), the total cases have surpassed 1,354 infections and 401 deaths (some sources say over 1,400 cases, with at least 1,333 confirmed EVD cases and 399 confirmed EVD deaths in the DRC, and 20 cases and 2 deaths in Uganda as of June 29). - The UN Development Programme (UNDP) warns that the outbreak could cost Africa up to $3.6 billion and push nearly a million people into poverty. - The CDC and WHO are actively responding. Let's fetch `https://www.cidrap.umn.edu/ebola/ebola-deaths-africa-top-400-uganda-reports-death-child-marburg` to get the latest exact figures and quotes on this outbreak. Let's do a web fetch.

This is an extremely detailed and highly relevant update on the Ebola Bundibugyo outbreak. Let's review the facts: - Total cases: At least 1,354 infections. - Total deaths: 401 deaths in the DRC and Uganda. - The disease has potentially spread to two new DRC provinces: Tshopo and Haut-Uele. - In Tshopo, authorities are tracing contacts of a pregnant woman who died of Ebola in Ituri on June 27 and was transported 186 miles by motorcycle to Kisangani. - In Haut-Uele, authorities apprehended two escaped isolated contacts from Ituri (one tested positive). - Uganda also confirmed an isolated Marburg case in a 1.5-year-old child who died in the Kyegegwa district. Let's organize our notes: We have two major updates: 1. **Amgen's Tavneos (avacopan)**: - The FDA hearing submission has been extended to **July 29, 2026** (originally June 29, 2026). - On June 29, 2026, the *New England Journal of Medicine* (NEJM) formally retracted the pivotal ADVOCATE trial paper (Jayne et al., 2021) because primary endpoint assessments in 9 patients were readjudicated after database lock and trial unblinding. - On June 26, 2026, the EMA's CHMP recommended revoking the marketing authorization for Tavneos in the EU due to GCP breaches in the ADVOCATE trial, rendering the data incorrect and misleading. - Amgen has hired the Duke Clinical Research Institute (DCRI) to perform an independent, fully blinded re-adjudication, which will be submitted to the FDA by July 29, 2026. - We should update `amgen-tavneos-eu-revocation-us-fda-extension` (or `amgen-tavneos-chmp-revocation-data-integrity` / `amgen-tavneos-fda-scrutiny-withdrawal-dispute`). Let's look at our list of notes. We have: - `amgen-tavneos-eu-revocation-us-fda-extension` (updated 2026-07-01T05:59:48Z, "Amgen's Tavneos Faces EU Revocation over Data Integrity as U.S. FDA Hearing Deadline is Extended and NEJM Retracts Pivotal Trial") - `amgen-tavneos-chmp-revocation-data-integrity` (updated 2026-06-30T05:18:01Z, "European CHMP Recommends Revoking Amgen's Tavneos (avacopan) Marketing Authorization Over Data Integrity and GCP Breaches") - `amgen-tavneos-fda-scrutiny-withdrawal-dispute` (updated 2026-07-01T05:14:40Z, "Amgen's Tavneos Withdrawal Fight Intensifies Over FDA Data Manipulation Letter and Japanese Safety Signal") Let's update `amgen-tavneos-eu-revocation-us-fda-extension` because it is the most recent and specifically covers the extension, EU revocation, and NEJM retraction. Wait, let's look at its preview. It says: "On June 29, 2026, the global regulatory and scientific crisis... reached a dramatic turning point. The New England Journal of Medicine..." Wait, let's update `amgen-tavneos-eu-revocation-us-fda-extension` with the exact NEJM retraction details and the July 29, 2026 extension details we fetched. 2. **FDA Regulatory Pivot & CBER OTP Churn**: - The FDA has accepted the BLA resubmissions for Capricor's deramiocel (PDUFA August 22, 2026; AdComm scheduled for July 29, 2026) and Replimune's RP1 (PDUFA August 2, 2026; AdComm expected late July). - This represents a significant pivot under acting FDA Commissioner Kyle Diamantas back to using advisory committees for contested applications. - Concurrently, Vijay Kumar (acting director of CBER's Office of Therapeutic Products (OTP)) is stepping down after exactly one year in office, marking continued leadership churn at CBER. - We should update `fda-regulatory-pivot-advisory-committees-capricor-replimune` with these details. 3. **Ebola Bundibugyo Outbreak**: - Total cases have surpassed 1,354 infections and deaths have topped 400 (401 deaths). - The outbreak is threatening to spread to two new DRC provinces (Tshopo and Haut-Uele), with intense contact tracing underway. - Uganda also reported a child's death from Marburg virus (unrelated to Ebola but highlighting the hemorrhagic fever burden). - We should update `bundibugyo-ebola-outbreak-drc-uganda` with these latest figures and developments. Let's write these notes. Let's check the watches we need to resolve or update: - `Amgen Tavneos FDA hearing submission and public docket close` (id: `019ec855-5381-7936-a3b6-a40d207e679d`). Since the deadline has been extended to July 29, 2026, we should record an event on this watch showing it has been extended, resolve it, and then record a new watch for July 29, 2026. Wait! Let's call `record_event` with `resolves: true` to close it, and then register a new watch for the July 29, 2026 deadline. - Let's call `record_event` on `019ec855-5381-7936-a3b6-a40d207e679d` showing that the deadline was extended to July 29, 2026. Let's write the notes first. I will draft the bodies carefully following the rules (no YAML frontmatter, title is first `# ` heading, slug is the stable slug, carry 1-2 representative verbatim quotes with links, interpret, and use wikilinks to link other findings). Let's start with `amgen-tavneos-eu-revocation-us-fda-extension`. I will write this note.

Now let's write the second note, which is the update to `fda-regulatory-pivot-advisory-committees-capricor-replimune`. I will write this note.

Now let's write the third note, which is the update to `bundibugyo-ebola-outbreak-drc-uganda`. I will write this note.

Now let's look at our watches and threads. We have the watch `Amgen Tavneos FDA hearing submission and public docket close` (thread_id: `019ec855-5381-7936-a3b6-a40d207e679d`). Let's record an event on it showing it has fired/resolved because the June 29 deadline has passed and the FDA extended the hearing submission deadline to July 29, 2026. Let's call `record_event` with `resolves: true` (to close this watch since the June 29 deadline has passed and the extension is a new dated event). Then we can register a new watch for the July 29, 2026 deadline. Wait, let's verify if there are other watches that can be updated. Let's see: - `FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy` (thread_id: `019f061f-f34a-7079-a276-d216329928b2`): Fire date is July 29, 2026. The trigger is: "Fires when the FDA Cellular, Tissue, and Gene Therapies Advisory Committee votes on or discusses the approval of deramiocel." This has not happened yet (it is scheduled for July 29, 2026). So we keep this watch open. - `FDA advisory committee meeting and PDUFA date for Replimune's RP1 in advanced melanoma` (thread_id: `019f0620-007b-7dab-87b4-0363a2496ea1`): PDUFA target action date is August 2, 2026. The advisory committee meeting is expected in late July 2026. This watch is active and should remain open. Let's call `record_event` on the Tavneos watch.

Excellent. Now let's register a new watch for the new July 29, 2026 deadline for Amgen's Tavneos hearing submission. This is a dated catalyst. Let's see: `watch_type: "dated_catalyst"`, `cardinality: "one_shot"`, `fire_date: "2026-07-29T00:00:00Z"`. I will register this watch.

This is perfect. Let's review if there are any other threads or watches we should open or resolve. We have resolved the Tavneos June 29 watch and replaced it with a July 29 watch. We have updated three existing findings with the latest, highly relevant evidence: 1. `amgen-tavneos-eu-revocation-us-fda-extension` 2. `fda-regulatory-pivot-advisory-committees-capricor-replimune` 3. `bundibugyo-ebola-outbreak-drc-uganda` Now, let's call `finish_cycle` to complete this research cycle. I will execute the tool call.

I have successfully completed the research cycle. Here is a summary of the findings and updates recorded in this cycle: 1. **Amgen's Tavneos (avacopan) Regulatory and Scientific Crisis**: - **NEJM Retraction**: On June 29, 2026, the *New England Journal of Medicine* formally retracted the pivotal ADVOCATE trial paper (first published in 2021) after an FDA investigation revealed that primary endpoint assessments in nine patients were readjudicated after database lock and trial unblinding. - **EU Revocation Recommendation**: On June 26, 2026, the EMA's CHMP recommended revoking the marketing authorization for Tavneos in the EU, citing GCP breaches that rendered the clinical data incorrect and misleading. - **FDA Deadline Extension**: The deadline for Amgen to submit its independent re-adjudication data (conducted by the Duke Clinical Research Institute) and its formal request for an FDA public hearing has been extended to **July 29, 2026**. - *Action*: Updated the existing note `amgen-tavneos-eu-revocation-us-fda-extension` and registered a new watch for the July 29, 2026 deadline, resolving the June 29 watch. 2. **FDA Regulatory Pivot and CBER Leadership Churn**: - **Advisory Committee Pivot**: Under acting FDA Commissioner Kyle Diamantas, the FDA has accepted BLA resubmissions for twice-rejected therapies and scheduled public advisory committee meetings. Capricor's BLA resubmission for deramiocel (DMD cardiomyopathy) was accepted with an **August 22, 2026** PDUFA date and a **July 29, 2026** advisory committee meeting. Replimune's third BLA resubmission for RP1 (advanced melanoma) was accepted with an **August 2, 2026** PDUFA date and an advisory committee meeting expected in late July. - **CBER OTP Leadership Churn**: On June 29, 2026, Vijay Kumar, the acting director of the Office of Therapeutic Products (OTP), stepped down after exactly one year in office. Active CBER Director Karim Mikhail will temporarily oversee the OTP. - *Action*: Updated the existing note `fda-regulatory-pivot-advisory-committees-capricor-replimune`. 3. **Ebola Bundibugyo Outbreak in the DRC and Uganda**: - **Mounting Toll**: Since being declared on May 15, 2026, the Bundibugyo Ebola outbreak has reached **1,354 infections** and **401 deaths** as of July 1, 2026. - **Provincial Spread**: The virus is spreading to two previously unaffected DRC provinces (Tshopo and Haut-Uele), triggering intense contact tracing. - **Concurrent Marburg Case**: Uganda confirmed an isolated, fatal case of Marburg virus in a 1.5-year-old child in Kyegegwa district. - *Action*: Updated the existing note `bundibugyo-ebola-outbreak-drc-uganda`.